Silence Therapeutics (NASDAQ:SLN) PT Raised to $49.00 at Morgan Stanley

Silence Therapeutics (NASDAQ:SLN) had its price target raised by Morgan Stanley from $45.00 to $49.00 in a research note published on Friday, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

A number of other analysts also recently issued reports on SLN. HC Wainwright reaffirmed a buy rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Thursday. Chardan Capital raised their target price on Silence Therapeutics from $42.00 to $55.00 and gave the stock a buy rating in a research note on Friday.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $19.00 on Friday. The stock’s fifty day moving average is $21.15 and its two-hundred day moving average is $20.95. Silence Therapeutics has a fifty-two week low of $4.84 and a fifty-two week high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Thursday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.18. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. The business had revenue of $15.73 million during the quarter, compared to the consensus estimate of $4.53 million. On average, equities analysts predict that Silence Therapeutics will post -1.52 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SLN. SG Americas Securities LLC acquired a new stake in shares of Silence Therapeutics during the 4th quarter worth about $110,000. Vivo Capital LLC acquired a new stake in shares of Silence Therapeutics during the 4th quarter worth about $8,862,000. Parkman Healthcare Partners LLC increased its position in shares of Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares during the last quarter. Redmile Group LLC acquired a new stake in shares of Silence Therapeutics during the 1st quarter worth about $43,798,000. Finally, Janus Henderson Group PLC acquired a new position in Silence Therapeutics in the 1st quarter valued at about $13,575,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.